Epo Biomarkers Market is increasingly gaining rapid traction with rising cases of cancer and ESRD in the U.S.
Erythropoietin (Epo) protein is a
naturally occurring hormone that can be found in the egg and in various other
animal species. This hormone has been proven to increase red blood cell
production. This is a very powerful growth factor and has shown promise in many
areas of medical research. One of the key reasons for the increased adoption of
EPO biomarkers is rising prevalence of end-stage renal disorders (ESRD). In
fact, in 2017, there were around 124,500 new cases of registered ESRD as per
the U.S. Renal Data System 2019 Annual Data Report. Such a high proportion of
cases has necessitated the adoption of epo biomarkers for the diagnosis of ESRD.
Furthermore, epo biomarkers can aid in the early detection of the disease,
thereby making the treatment more effective and efficient. Hence, such factors
can stimulate growth of the epo biomarkers market.
Erythropoietin proteins are used in
many medical applications and are useful for many years to come. It is a
natural protein that can be found in the body and it can be used by both the
body and by doctors to detect iron deficiency anemia. In fact, this is a
popular and successful technology used today in the field of genetic medicine.
Other major factors that have led to the high adoption of epo biomarkers are
increasing launch of erythropoietin alfa for cancer patients who are suffering
from anemia. Recently, in May 2018, the U.S. Food and Drug Administration (FDA)
approved Retacrit as a biosimilar to Epogen/Procrit for the treatment of anemia
caused by chronic kidney disease, use of zidovudine, or chemotherapy. Thus,
these factors can augment growth of the epo
biomarkers market in the near future.
As far as the regional footprint is
concerned, North America region seems to be gaining robust traction in the epo
biomarkers market. This is typically due to the fact there is a high prevalence
of cancer and the presence of robust healthcare infrastructure. As per the
National Cancer Institute, in 2020, around 1,806,590 new cases of cancer were
expected to be diagnosed in the U.S. with around 606,520 deaths. On the
contrary, Asia Pacific is exhibiting promising signs since there is a presence
of key market players such as Shandong Kexing Bioproducts Co. Ltd., Biocon
Ltd., Intas Pharmaceuticals Ltd., and 3Sbio Group.
One of the most exciting areas of
research with respect to erythropoietin biomarkers is for the treatment and
prevention of renal diseases. Preventing and treating renal diseases is one of
the biggest challenges for scientists. Regardless of its advantages, epo
biomarkers do have certain shortcomings that could limit their adoption. The
overproduction of red blood cells due to over-expressions of epo biomarkers can
lead to absolute polycythemia. Thus, such conditions can potentially impede
growth of the epo biomarkers market in the near future.
Comments
Post a Comment